International Congress Munich 2014


Beyond tyrosine kinase inhibition: promising new developments in molecular oncology

Symposium
Chairs: J. Cadranel (Paris, France), M. Remmelink (Brussels, Belgium)
Aims: The goal of this symposium is to provide an overview of fundamental biological and immunological principals of lung cancer biology beyond the tyrosine kinase inhibitor-induced inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). The mode of action of therapeutics that are being assessed currently will be presented. Skilled speakers, all of them experienced clinicians and scientists, will highlight how to translate the latest science into clinical practice with respect to the early diagnosis, prognosis and therapy of thoracic malignancies.
Immunology-based therapeutic strategies in lung cancer and mesothelioma
S. Albelda (Philadelphia, United States of America)
WebcastSlide presentationMultimedia files
WebcastSlide presentationMultimedia files
Genome-wide chip arrays from diagnostic specimens as the basis for therapy
P. Micke (Uppsala, Sweden)
WebcastSlide presentationMultimedia files
WebcastSlide presentationMultimedia files
International molecular testing guidelines in clinical practice
R. G. Wiewrodt (Muenster, Germany)
Slide presentation
Slide presentation